Plasminogen activator inhibitor-1 and the circadian clock in metabolic disorders

Clinical and Experimental Hypertension

Volumn 31, Issue 3, 2009, Pages 208-219

  Oishi, Katsutaka ^a,b  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^b MUSASHINO UNIVERSITY   (Japan)

Author keywords

Adipose tissue; Circadian clock genes; Circadian rhythm; Diabetes; Liver; Obesity

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 7; FIBRINOGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN BMAL1; PROTEIN C; PROTEIN S; TISSUE FACTOR PATHWAY INHIBITOR; TRANSCRIPTION FACTOR CLOCK; VASOPRESSIN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; TRANSACTIVATOR PROTEIN;

BEHAVIOR; BLOOD PRESSURE; BODY TEMPERATURE; BRAIN INFARCTION; CARDIOVASCULAR RISK; CIRCADIAN RHYTHM; DIABETES MELLITUS; FIBRINOLYSIS; GENE EXPRESSION; HEART INFARCTION; HEART RATE; HORMONE RELEASE; HUMAN; INCIDENCE; METABOLIC DISORDER; METABOLISM; NEGATIVE FEEDBACK; NONHUMAN; OBESITY; PROTEIN BLOOD LEVEL; REVIEW; RODENT; SLEEP WAKING CYCLE; SUDDEN DEATH; SUPRACHIASMATIC NUCLEUS; ANIMAL; DISEASE MODEL; GENETICS; MOUSE; MUTATION; PHYSIOLOGY;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CIRCADIAN RHYTHM; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MUTATION; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANS-ACTIVATORS;

EID: 67649963666     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960902822468     Document Type: Review

References (71)

1. Vaughan DE, Declerck PJ, Van Houtte E, De Mol M, Collen D. Studies of recombinant plasmi-nogen activator inhibitor-1 in rabbits. Pharmacokinetics and evidence for reactivation of latent plasminogen activator inhibitor-1 in vivo. Circ Res 1990;67:1281-1286.
2. Mutch NJ, Wilson HM, Booth NA. Plasminogen activator inhibitor-1 and haemostasis in obesity. Proc Nutr Soc 2001;60:341-347.
3. Eren M, Painter CA, Gleaves LA, Schoenhard JA, Atkinson JB, Brown NJ, Vaughan DE. Tissue- and agonist-specific regulation of human and murine plasminogen activator inhibitor-1 promoters in transgenic mice. J Thromb Haemost 2003;1:2389-2396.
4. Skurk T, Hauner H. Obesity and impaired fibrinolysis: Role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 2004;28:1357-1364.
5. Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost 2005;3:1879-1883.
6. Mertens I, Van Gaal LF. Visceral fat as a determinant of fibrinolysis and hemostasis. Semin Vasc Med 2005;548-55.
7. Andreotti F, Kluft C. Circadian variation of fibrinolytic activity in blood. Chronobiol Int 1991;8:336-351.
8. Curtis AM, Fitzgerald GA. Central and peripheral clocks in cardiovascular and metabolic function. Ann Med 2006;38:552-559.
9. Reilly DF, Westgate EJ, Fitzgerald GA. Peripheral circadian clocks in the vasculature. Arterioscler Thromb Vasc Biol 2007;27:1694-1705.
10. Reppert SM, Weaver DR. Molecular analysis of mammalian circadian rhythms. Annu Rev Physiol 2001;63:647-676.
11. Wijnen H, Young MW. Interplay of circadian clocks and metabolic rhythms. Annu Rev Genet 2006;40:409-448.
12. Richter HG, Torres-Farfan C, Rojas-Garcia PP, Campino C, Torrealba F, Seron-Ferre M. The circadian timing system: making sense of day/night gene expression. Biol Res 2004;37:11-28.
13. Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature 2002;418:935-941.
14. Dardente H, Cermakian N. Molecular circadian rhythms in central and peripheral clocks in mammals. Chronobiol Int 2007;24:195-213.
15. Vitaterna MH, King DP, Chang AM, Kornhauser JM, Lowrey PL, McDonald JD, Dove WF, Pinto LH, Turek FW, Takahashi JS. Mutagenesis and mapping of a mouse gene, Clock, essential for circadian behavior. Science 1994;264:719-725.
16. Oishi K, Sakamoto K, Okada T, Nagase T, Ishida N. Antiphase circadian expression between BMAL1 and period homologue mRNA in the suprachiasmatic nucleus and peripheral tissues of rats. Biochem Biophys Res Commun 1998;253:199-203.
17. Oishi K, Sakamoto K, Okada T, Nagase T, Ishida N. Humoral signals mediate the circadian expression of rat period homologue (rPer2) mRNA in peripheral tissues. Neurosci Lett 1998;256:117-119.
18. Sakamoto K, Nagase T, Fukui H, Horikawa K, Okada T, Tanaka H, Sato K, Miyake Y, Ohara O, Kako K, Ishida N. Multitissue circadian expression of rat period homolog (rPer2) mRNA is governed by the mammalian circadian clock, the suprachiasmatic nucleus in the brain. J Biol Chem 1998;273:27039-27042.
19. Panda S, Antoch MP, Miller BH, Su AI, Schook AB, Straume M, Schultz PG, Kay SA, Takahashi JS, Hogenesch JB. Coordinated transcription of key pathways in the mouse by the circadian clock. Cell 2002;109:307-320.
20. Oishi K, Miyazaki K, Kadota K, Kikuno R, Nagase T, Atsumi G, Ohkura N, Azama T, Mesaki M, Yukimasa S, Kobayashi H, Iitaka C, Umehara T, Horikoshi M, Kudo T, Shimizu Y, Yano M, Monden M, Machida K, Matsuda J, Horie S, Todo T, Ishida N. Genome-wide expression analysis of mouse liver reveals CLOCK-regulated circadian output genes. J Biol Chem 2003;27841519-41527.
21. Oishi K, Shirai H, Ishida N. CLOCK is involved in the circadian transactivation of peroxisome-proliferator-activated receptor alpha (PPARalpha) in mice. Biochem J 2005;386:575-581.
22. Oishi K, Fukui H, Ishida N. Rhythmic expression of BMAL1 mRNA is altered in Clock mutant mice: differential regulation in the suprachiasmatic nucleus and peripheral tissues. Biochem Biophys Res Commun 2000;268:164-171.
23. Ripperger JA, Shearman LP, Reppert SM, Schibler U. CLOCK, an essential pacemaker component, controls expression of the circadian transcription factor DBP. Genes Dev 2000;14:679-689.
24. Jin X, Shearman LP, Weaver DR, Zylka MJ, de Vries GJ, Reppert SM. A molecular mechanism regulating rhythmic output from the suprachiasmatic circadian clock. Cell 1999;96:57-68.
25. Cheng MY, Bullock CM, Li C, Lee AG, Bermak JC, Belluzzi J, Weaver Dr, Leslie FM, Zhou QY. Prokineticin 2 transmits the behavioural circadian rhythm of the suprachiasmatic nucleus. Nature 2002;417:405-410.
26. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. Science 2003;302:255-259.
27. Maemura K, de la Monte SM, Chin MT, Layne MD, Hsieh CM, Yet SF, Perrella MA, Lee ME. CLIF, a novel cycle-like factor, regulates the circadian oscillation of plasminogen activator inhibitor-1 gene expression. J Biol Chem 2000;275:36847-36851.
28. Manfredini R, Boari B, Smolensky MH, Salmi R, la Cecilia O, Maria Malagoni A, Haus E, Manfredini F. Circadian variation in stroke onset: identical temporal pattern in ischemic and hemorrhagic events. Chronobiol Int 2005;22:417-453.
29. Nordt TK, Peter K, Ruef J, Kubler W, Bode C. Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease. Thromb Haemost 1999;82 suppl 1:14-18.
30. Haus E, Cusulos M, Sackett-Lundeen L, Swoyer J. Circadian variations in blood coagulation parameters, alpha-antitrypsin antigen and platelet aggregation and retention in clinically healthy subjects. Chronobiol Int 1990;7:203-216.
31. Pinotti M, Bertolucci C, Portaluppi F, Colognesi I, Frigato E, Foa A, Bernardi F. Daily and cir-cadian rhythms of tissue factor pathway inhibitor and factor VII activity. Arterioscler Thromb Vasc Biol 2005;25:646-649.
32. Undar L, Ertugrul C, Altunbas H, Akca S. Circadian variations in natural coagulation inhibitors protein C, protein S and antithrombin in healthy men: a possible association with interleukin-6. Thromb Haemost 1999;81:571-575.
33. Schoenhard JA, Smith LH, Painter CA, Eren M, Johnson CH, Vaughan DE. Regulation of the PAI-1 promoter by circadian clock components: differential activation by BMAL1 and BMAL2. J Mol Cell Cardiol 2003;35:473-481.
34. Wang J, Yin L, Lazar MA. The orphan nuclear receptor Rev-erb alpha regulates circadian expression of plasminogen activator inhibitor type 1. J Biol Chem 2006;281:33842-33848.
35. Oishi K, Ohkura N, Kasamatsu M, Fukushima N, Shirai H, Matsuda J, Ishida N. Tissue-specific augmentation of circadian PAI-1 expression in mice with streptozotocin-induced diabetes. Thromb Res 2004;114:129-135.
36. Oishi K, Ohkura N, Amagai N, Ishida N. Involvement of circadian clock gene Clock in diabetes-induced circadian augmentation of plasminogen activator inhibitor-1 (PAI-1) expression in the mouse heart. FEBS Lett 2005;579:3555-3559.
37. Ohkura N, Oishi K, Fukushima N, Kasamatsu M, Atsumi GI, Ishida N, Horio S, Matsuda J, et al. Circadian clock molecules CLOCK and CRYs modulate fibrinolytic activity by regulating the PAI-1 gene expression. J Thromb Haemost 2006;4:2478-2485.
38. King DP, Zhao Y, Sangoram AM, Wilsbacher LD, Tanaka M, Antoch MP, Steeves TD, Vitaterna MH, Kornhauser JM, Lowrey PL, Turek FW, Takahashi JS. Positional cloning of the mouse circadian clock gene. Cell 1997;89:641-653.
39. Oishi K, Shirai H, Ishida N. Identification of the circadian clock-regulated E-box element in the mouse plasminogen activator inhibitor-1 gene. J Thromb Haemost 2007;5:428-431.
40. van der Bom JG, Bots ML, Haverkate F, Kluft C, Grobbee DE. The 4G5G polymorphism in the gene for PAI-1 and the circadian oscillation of plasma PAI-1. Blood 2003;101:1841-1844.
41. Dimova EY, Kietzmann T. Cell type-dependent regulation of the hypoxia-responsive plasminogen activator inhibitor-1 gene by upstream stimulatory factor-2. J Biol Chem 2006;281: 2999-3005.
42. Nesto RW. Correlation between cardiovascular disease and diabetes mellitus: current concepts. Am J Med 2004;116 suppl 5A:11S-22S.
43. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006;444:875-880.
44. Yamamoto K, Saito H. A pathological role of increased expression of plasminogen activator inhibitor-1 in human or animal disorders. Int J Hematol 1998;68:371-385.
45. Aronson D. Impaired modulation of circadian rhythms in patients with diabetes mellitus: a risk factor for cardiac thrombotic events? Chronobiol Int 2001;18:109-121.
46. Anand SS, Yi Q, Gerstein H, Lonn E, Jacobs R, Vuksan V, Teo K, Davis B, Montague P, Yusuf S. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 2003;108:420-425.
47. Tsikouris JP, Suarez JA, Meyerrose GE. Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents. J Clin Pharmacol 2002;42:1187-1199.
48. Trost S, Pratley R, Sobel B. Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes. Curr Diab Rep 2006;647-54.
49. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006;26:2200-2207.
50. Samad F, Loskutoff DJ. The fat mouse: a powerful genetic model to study elevated plasminogen activator inhibitor 1 in obesity/NIDDM. Thromb Haemost 1997;78:652-655.
51. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996;2:800-803.
52. Samad F, Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med 1996;2:568-582.
53. Oishi K, Ohkura N, Wakabayashi M, Shirai H, Sato K, Matsuda J, Atsumi G, Ishida N. CLOCK is involved in obesity-induced disordered fibrinolysis in ob/ob mice by regulating PAI-1 gene expression. J Thromb Haemost 2006;4:1774-1780.
54. Lijnen HR, Alessi MC, Van Hoef B, Collen D, Juhan-Vague I. On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. J Thromb Haemost 2005;3:1174-1179.
55. Alessi MC, Juhan-Vague I. Contribution of PAI-1 in cardiovascular pathology. Arch Mal Coeur Vaiss 2004;97:673-678.
56. Oishi K, Ohkura N, Matsuda J, Ishida N. Food deprivation induces adipose PAI-1 expression without accumulation of plasma PAI-1 in genetically obese and diabetic db/db mice. Thromb Haemost 2007;98:864-870.
57. Oishi K, Atsumi G, Sugiyama S, Kodomari I, Kasamatsu M, Machida K, et al. Disrupted fat absorption attenuates obesity induced by a high-fat diet in Clock mutant mice. FEBS Lett 2006;580:127-130.
58. Turek FW, Joshu C, Kohsaka A, Lin E, Ivanova G, McDearmon E, Laposky A, Losee-Olson S, Easton A, Jensen DR, Eckel RH, Takahashi JS, Bass J. Obesity and metabolic syndrome in circadian Clock mutant mice. Science 2005;308:1043-1045.
59. Kudo T, Tamagawa T, Kawashima M, Mito N, Shibata S. Attenuating Effect of Clock Mutation on Triglyceride Contents in the ICR Mouse Liver under a High-Fat Diet. J Biol Rhythms 2007;22:312-323.
60. Oishi K, Kasamatsu M, Ishida N. Gene- and tissue-specific alterations of circadian clock gene expression in streptozotocin-induced diabetic mice under restricted feeding. Biochem Biophys Res Commun 2004;317:330-334.
61. Ando H, Oshima Y, Yanagihara H, Hayashi Y, Takamura T, Kaneko S, Fujimura A. Profile of rhythmic gene expression in the livers of obese diabetic KK-A(y) mice. Biochem Biophys Res Commun 2006;346:1297-1302.
62. Ando H, Yanagihara H, Hayashi Y, Obi Y, Tsuruoka S, Takamura T, Kaneko S, Fujimura A. Rhythmic messenger ribonucleic acid expression of clock genes and adipocytokines in mouse visceral adipose tissue. Endocrinology 2005;146:5631-5636.
63. Kudo T, Akiyama M, Kuriyama K, Sudo M, Moriya T, Shibata S. Night-time restricted feeding normalises clock genes and Pai-1 gene expression in the db/db mouse liver. Diabetologia 2004;47:1425-1436.
64. Yanagihara H, Ando H, Hayashi Y, Obi Y, Fujimura A. High-fat feeding exerts minimal effects on rhythmic mRNA expression of clock genes in mouse peripheral tissues. Chronobiol Int 2006;23:905-914.
65. Shimba S, Ishii N, Ohta Y, Ohno T, Watabe Y, Hayashi M, Wada T, Aoyagi T, Tezuka M. Brain and muscle Arnt-like protein-1 (BMAL1), a component of the molecular clock, regulates adipogenesis. Proc Natl Acad Sci USA 2005;102:12071-12076.
66. Fonseca VA, Reynolds T, Hemphill D, Randolph C, Wall J, Valiquet TR, Graveline I, Fink LM. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 1998;12:181-186.
67. Ghanim H, Garg R, Aljada A, Mohanty P, Kumbkarni Y, Assian E, Hamouda W, Dandona P. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001;86:1306-1312.
68. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004;89:2728-2735.
69. Aljada A, Garg R, Ghanim H, Mohanty P, Hamouda W, Assian E, Dandona P. Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? J Clin Endocrinol Metab 2001;86:3250-3256.
70. Curtis AM, Seo SB, Westgate EJ, Rudic RD, Smyth EM, Chakravarti D, FitzGerald GA, McNamara P. Histone acetyltransferase-dependent chromatin remodeling and the vascular clock. J Biol Chem 2004;279: 7091-7097.
71. Doi M, Hirayama J, Sassone-Corsi P. Circadian regulator CLOCK is a histone acetyltransferase. Cell 2006;125:497-508.